Ninfa Marlen Chaves-Torres1,2, Santiago Fadul3, Jesus Patiño1, Eduardo Netto4. 1. Postgraduate Program in Medicine and Health, Federal University of Bahia, Salvador, Brazil. 2. Faculty of Medicine and Health Sciences, Military University Nueva Granada, Bogotá, Colombia. 3. Department of Communicable Diseases, Respiratory Diseases Team, National Institute of Health, Bogotá, Colombia. 4. Postgraduate Program in Medicine and Health, Federal University of Bahia, José Silveira Foundation, Salvador, Brazil.
Abstract
BACKGROUND: Multidrug- and rifampicin (RMP)-resistant tuberculosis (MDR/RR-TB) requires prolonged and expensive treatment, which is difficult to sustain in the Colombian health system. This requires the joint action of different providers to provide timely health services to people with TB. Identifying factors associated with unfavorable treatment outcomes in patients with MDR/RR-TB who received drug therapy between 2013 and 2015 in Colombia can help guide the strengthening of the national TB control program. METHOD: A retrospective cohort study was conducted with all patients who received treatment for MDR/RR-TB between January 2013 and December 2015 in Colombia who were registered and followed up by the national TB control program. A multivariate logistic regression model was used to estimate the associations between the exposure variables with the response variable (treatment outcome). RESULTS: A total of 511 patients with MDR/RR-TB were registered and followed up by the national TB control program in Colombia, of whom 16 (3.1%) had extensive drug resistance, 364 (71.2%) had multidrug resistance, and 131 (25.6%) had RMP monoresistance. The mean age was 39.9 years (95% confidence interval (CI): 38.5-41.3), most patients were male 285 (64.6%), and 299 (67.8%) were eligible for subsidized health services. The rate of unfavorable treatment outcomes in the RR-TB cohort was 50.1%, with rates of 85.7% for patients with extensive drug resistance, 47.6% for patients with multidrug resistance, and 52.6% for patients with RMP monoresistance. The 511 MDR/RR-TB patients were included in bivariate and multivariate analyses, patients age ≥ 60 years (crude odds ratio (ORc) = 2.4, 95% CI 1.1-5.8; adjusted odds ratio (ORa) = 2.7, 95% CI 1.1-6.8) and subsidized health regime affiliation (ORc = 3.6, 95% CI 2.3-5.6; ORa = 3.4, 95% CI 2.0-6.0) were associated with unfavorable treatment outcomes. CONCLUSION: More than 50% of the patients with MDR/RR-TB in Colombia experienced unfavorable treatment outcomes. The patients who were eligible for subsidized care were more likely to experience unfavorable treatment outcomes. Those who were older than 60 years were also more likely to experience unfavorable treatment outcomes.
BACKGROUND: Multidrug- and rifampicin (RMP)-resistant tuberculosis (MDR/RR-TB) requires prolonged and expensive treatment, which is difficult to sustain in the Colombian health system. This requires the joint action of different providers to provide timely health services to people with TB. Identifying factors associated with unfavorable treatment outcomes in patients with MDR/RR-TB who received drug therapy between 2013 and 2015 in Colombia can help guide the strengthening of the national TB control program. METHOD: A retrospective cohort study was conducted with all patients who received treatment for MDR/RR-TB between January 2013 and December 2015 in Colombia who were registered and followed up by the national TB control program. A multivariate logistic regression model was used to estimate the associations between the exposure variables with the response variable (treatment outcome). RESULTS: A total of 511 patients with MDR/RR-TB were registered and followed up by the national TB control program in Colombia, of whom 16 (3.1%) had extensive drug resistance, 364 (71.2%) had multidrug resistance, and 131 (25.6%) had RMP monoresistance. The mean age was 39.9 years (95% confidence interval (CI): 38.5-41.3), most patients were male 285 (64.6%), and 299 (67.8%) were eligible for subsidized health services. The rate of unfavorable treatment outcomes in the RR-TB cohort was 50.1%, with rates of 85.7% for patients with extensive drug resistance, 47.6% for patients with multidrug resistance, and 52.6% for patients with RMP monoresistance. The 511 MDR/RR-TBpatients were included in bivariate and multivariate analyses, patients age ≥ 60 years (crude odds ratio (ORc) = 2.4, 95% CI 1.1-5.8; adjusted odds ratio (ORa) = 2.7, 95% CI 1.1-6.8) and subsidized health regime affiliation (ORc = 3.6, 95% CI 2.3-5.6; ORa = 3.4, 95% CI 2.0-6.0) were associated with unfavorable treatment outcomes. CONCLUSION: More than 50% of the patients with MDR/RR-TB in Colombia experienced unfavorable treatment outcomes. The patients who were eligible for subsidized care were more likely to experience unfavorable treatment outcomes. Those who were older than 60 years were also more likely to experience unfavorable treatment outcomes.
Authors: Nafees Ahmad; Shama D Ahuja; Onno W Akkerman; Jan-Willem C Alffenaar; Laura F Anderson; Parvaneh Baghaei; Didi Bang; Pennan M Barry; Mayara L Bastos; Digamber Behera; Andrea Benedetti; Gregory P Bisson; Martin J Boeree; Maryline Bonnet; Sarah K Brode; James C M Brust; Ying Cai; Eric Caumes; J Peter Cegielski; Rosella Centis; Pei-Chun Chan; Edward D Chan; Kwok-Chiu Chang; Macarthur Charles; Andra Cirule; Margareth Pretti Dalcolmo; Lia D'Ambrosio; Gerard de Vries; Keertan Dheda; Aliasgar Esmail; Jennifer Flood; Gregory J Fox; Mathilde Fréchet-Jachym; Geisa Fregona; Regina Gayoso; Medea Gegia; Maria Tarcela Gler; Sue Gu; Lorenzo Guglielmetti; Timothy H Holtz; Jennifer Hughes; Petros Isaakidis; Leah Jarlsberg; Russell R Kempker; Salmaan Keshavjee; Faiz Ahmad Khan; Maia Kipiani; Serena P Koenig; Won-Jung Koh; Afranio Kritski; Liga Kuksa; Charlotte L Kvasnovsky; Nakwon Kwak; Zhiyi Lan; Christoph Lange; Rafael Laniado-Laborín; Myungsun Lee; Vaira Leimane; Chi-Chiu Leung; Eric Chung-Ching Leung; Pei Zhi Li; Phil Lowenthal; Ethel L Maciel; Suzanne M Marks; Sundari Mase; Lawrence Mbuagbaw; Giovanni B Migliori; Vladimir Milanov; Ann C Miller; Carole D Mitnick; Chawangwa Modongo; Erika Mohr; Ignacio Monedero; Payam Nahid; Norbert Ndjeka; Max R O'Donnell; Nesri Padayatchi; Domingo Palmero; Jean William Pape; Laura J Podewils; Ian Reynolds; Vija Riekstina; Jérôme Robert; Maria Rodriguez; Barbara Seaworth; Kwonjune J Seung; Kathryn Schnippel; Tae Sun Shim; Rupak Singla; Sarah E Smith; Giovanni Sotgiu; Ganzaya Sukhbaatar; Payam Tabarsi; Simon Tiberi; Anete Trajman; Lisa Trieu; Zarir F Udwadia; Tjip S van der Werf; Nicolas Veziris; Piret Viiklepp; Stalz Charles Vilbrun; Kathleen Walsh; Janice Westenhouse; Wing-Wai Yew; Jae-Joon Yim; Nicola M Zetola; Matteo Zignol; Dick Menzies Journal: Lancet Date: 2018-09-08 Impact factor: 79.321
Authors: G Obregón; K Zevallos; V Alarcón; Z M Puyén; O Chávez Inagaki; A Mendoza-Ticona; E Alarcón-Arrascue; E Heldal; D A J Moore Journal: Int J Tuberc Lung Dis Date: 2018-11-01 Impact factor: 2.373
Authors: Daniel J Carter; Rhian Daniel; Ana W Torrens; Mauro N Sanchez; Ethel Leonor N Maciel; Patricia Bartholomay; Draurio C Barreira; Davide Rasella; Mauricio L Barreto; Laura C Rodrigues; Delia Boccia Journal: BMJ Glob Health Date: 2019-01-24
Authors: Kefyalew Addis Alene; Kerri Viney; Darren J Gray; Emma S McBryde; Zuhui Xu; Archie C A Clements Journal: PLoS One Date: 2020-01-03 Impact factor: 3.240
Authors: Farman Ullah Khan; Asim Ur Rehman; Faiz Ullah Khan; Khezar Hayat; Amjad Khan; Nafees Ahmad; Jie Chang; Usman Rashid Malik; Yu Fang Journal: Int J Environ Res Public Health Date: 2022-01-29 Impact factor: 3.390